Cargando…
Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
Resistance to anti-cancer drugs has proved to be a major barrier in the clinical management of neoplastic disease. We have investigated the mechanistic basis for resistance to folate-based thymidylate synthase (TS) inhibitors using two cell lines selected for resistance to ZD1694 (N-(5-[N-(3,4-dihyd...
Autores principales: | Freemantle, S. J., Jackman, A. L., Kelland, L. R., Calvert, A. H., Lunec, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033779/ https://www.ncbi.nlm.nih.gov/pubmed/7537519 |
Ejemplares similares
-
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
por: Jackman, A. L., et al.
Publicado: (1995) -
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
por: Aherne, G. W., et al.
Publicado: (1998) -
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
por: Smith, I., et al.
Publicado: (1996) -
The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.
por: Walton, M. I., et al.
Publicado: (1998) -
Biological Activity and Intracellular Metabolism of ZD1694 in Human Leukemia Cell Lines with Different Resistance Mechanisms to Antifolate Drugs
por: Takemura, Yuzuru, et al.
Publicado: (1996)